High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma
To evaluate the role of allogeneic hematopoietic cell transplantation in the treatment of NHL.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- Laura Johnston, MD
- Wen-Kai Weng, MD, PhD
- Robert Lowsky, MD
- Sandra Horning
- Sally Arai, MD
- Ginna G. Laport
- Judith Shizuru, Ph.D., M.D.
- Ronald Levy, MD
- procedure : ablative allogeneic hematopoietic cell transplantation
Phase: Phase 2
Ages Eligible For Study:
Morphologically confirmed relapsed non-Hodgkin's lymphoma Age: >18 and <61 years of age Signed informed consent